ClearPoint Neuro, a medical device and therapy company, reported $10.9 million in revenue for the second quarter of 2026, up 18% year over year.
Neurosurgery navigation and therapy revenue increased 62% to $5.6 million from $3.4 million, while biologics and drug delivery revenue declined 15%, according to an Aug. 3 news release from the company. Capital equipment and software revenue increased 24% to $1.3 million from $1 million.
The company reported a net loss of $11.3 million for the quarter, compared with a $5.8 million net loss during the same period in 2025. Operating expenses increased 51% to $17 million from $11.2 million.
ClearPoint Neuro said it expects its 2026 revenue to be between $48 million and $52 million.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
